Key indicators: single-crystal X-ray study; T = 298 K; mean (C-C) = 0.002 Å; R factor = 0.043; wR factor = 0.123; data-to-parameter ratio = 17.9.
Related literature
For the biological activity of quinazoline-4(3H)-one derivatives, see: Pandeya et al. (1999) ; Shiba et al. (1997) ; Malamas & Millen (1991) ; Mannschreck et al. (1984) ; Kung et al. (1999) ; Bartroli et al. (1998) ; Palmer et al. (1997) ; Tsou et al. (2001) ; Matsuno et al. (2002) . For the synthesis of the title compound, see : Yang et al. (2008) .
Experimental
Crystal data Table 1 Hydrogen-bond geometry (Å , ). Data collection: SMART (Bruker, 2000); cell refinement: SAINT (Bruker, 2000); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 ); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008) ; molecular graphics: SHELXTL (Sheldrick, 2008) ; software used to prepare material for publication: SHELXTL.
2-Anilino-3-(2-hydroxyphenyl)quinazolin-4(3H)-one methanol monosolvate B. Liu, X.-B. Chen, X.-H. Yang, D.-F. Pan and J.-K. Ma Comment Quinazoline-4(3H)-one derivatives have numerous biological properties. Some of these activities include antimicrobial (Pandeya et al., 1999; Shiba et al., 1997 ), antidiabetic (Malamas & Millen, 1991 ), anticonvulsant (Mannschreck et al., 1984 , antibacterial (Kung et al., 1999 ), antifungal (Bartroli et al., 1998 , protein tyrosine kinase inhibitors (Palmer et al., 1997) , EGFR inhibitors (Tsou et al., 2001) and PDGFR phosphorylation inhibitors (Matsuno et al., 2002) . We have recently focused on the synthesis of heterocyclic compounds using an aza-Wittig reaction. We present here the crystal structure of the title compound, (I) (Fig. 1) , which can be used as a precursor for obtaining bioactive molecules.
In the crystal structure, the pyrimidinone heterocycle and the adjacent benzene ring are not planar, but inclined at 1.73 (6)°.
Significant intermolecular O-H···O and C-H···O and intramolecular O-H···O contribute strongly to the stability of the molecular configuration (Table 1 and Fig. 2 ).
The title compound was prepared according to the literature method of Yang et al. (2008) . To a solution of iminophosphorane (1.40 g, 3.0 mmol) in anhydrous THF (10 ml) was added isocyanatobenzene (3 mmol) under nitrogen at room temperature.
After reaction, the mixture was allowed to stand for 10 h at 273-278 K, the solvent was removed under reduced pressure and diethyl ether/petroleum ether (1:2 v/v, 20 ml) was added to precipitate triphenylphosphine oxide. After filtration, the solvent was removed to give 1-phenyl-3-(2-ethoxycarbonylphenyl) carbodiimide, which was used directly without further purification. To a solution of 1-phenyl-3-(2-ethoxycarbonylphenyl) carbodiimide in THF (15 ml) was added 2-aminophenol (3 mmol). After the reaction mixture was allowed to stand for 0.5 h, the solvent was removed and anhydrous ethanol (10 ml) with several drops of EtONa in EtOH was added. The mixture was stirred for 2 h at room temperature. The solution was concentrated under reduced pressure and the residue was recrystallized from ethanol to give the title compound, (I). The product was recrystallized from methanol-dichloromethane (1:1 v/v, 20 ml) at room temperature to give crystals suitable for X-ray diffraction (yield 85%).
Refinement
All C-bound H atoms were located at their ideal positions with C-H = 0.93 Å (aromatic) and 0.96 Å (methyl), and refined as riding, with U iso (H) = 1.2U eq (C) for aromatic and 1.5U eq (C) for methyl H atoms. H atoms bonded to N and O atoms were found in a difference map and then refined with distance restraints of N-H = 0.85 (2) Å and O-H = 0.90 (2) Å. The U iso (H) values were set k times of their carrier atoms (k = 1.2 for N and 1.5 for O atoms).
supplementary materials sup-2 Figures   Fig. 1 . View of the molecular structure of (I), showing the atom labelling scheme and with displacement ellipsoids drawn at the 50% probability level. 
